in the treatment of attention- deficit/ hyperactivity disorder: pharmacokinetics, efficacy and safety in children and adolescents.
Long-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate
to address continuing clinical challenges.
In another study, 157 patients aged 6-17 years with ADHD and well controlled on treatment with lisdexamfetamine dimesylate
(Vyvanse) were randomized to continued treatment or drug withdrawal.
According to its current diagnostic criteria in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, the patent includes the use of the amphetamine prodrug lisdexamfetamine dimesylate
(l-lysine-d-amphetamine) alone, or in combination with other pharmacologic therapies, for the treatment of Binge Eating Disorder.
Activity in the regions of the brain associated with motivation and reward correlated with clinical improvements in attention-deficit / hyperactivity disorder symptoms in adults given lisdexamfetamine dimesylate
, the results of an imaging study have shown.
improves processing speed and memory in cognitively impaired MS patients: a phase II study.
The treatment is called lisdexamfetamine dimesylate
and is aimed initially at six to 18-year-olds.
Generally, lisdexamfetamine dimesylate
(Vyvanse) and methylphenidate (Ritalin), known as "stimulant" drugs, are prescribed for the condition.
Stimulant medications--such as lisdexamfetamine dimesylate
(Vyvanse) and methylphenidate (Ritalin)--are most commonly prescribed for ADHD.